Bezafibrate for primary biliary cholangitis patients
Treatments studied
Part of Digestive system clinical trials.
This trial studies whether bezafibrate, a medication, can help people with primary biliary cholangitis (PBC). You may be considered if your care team is already considering bezafibrate and you meet safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a patient with primary biliary cholangitis (PBC) whose doctor is offering bezafibrate treatment
- You must be age 18 or older
- You should not have an expected life span of less than 6 months
- You must not have known cancer
- You must not have other planned liver transplant within the next 6 months
- You must not have other known liver causes such as viral hepatitis, autoimmune liver disease, heavy alcohol-related liver disease, or fatty liver disease (NAFLD/NASH)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a specific blood marker (sCD163) changes in people newly diagnosed with primary biliary cholangitis (PBC). It’s mainly meant to see whether this marker could help predict treatment response, especially before starting UDCA.
This trial tests whether the drug fenofibrate can help people with primary biliary cholangitis (PBC), a chronic liver disease. It is for patients who have already taken fenofibrate in a previous study and want to continue treatment.
This trial tests if adding bezafibrate (200 mg or 400 mg) to standard UDCA treatment can improve liver function in people with primary biliary cholangitis whose UDCA alone isn't working well enough.
This study tests whether fenofibrate, a medicine that lowers fats in the blood, can help people with primary biliary cholangitis (a chronic liver disease) who haven't had treatment before. It aims to see if it is safe and effective as a first treatment option.
This trial studies whether fenofibrate (a cholesterol medicine) can improve outcomes in people with primary biliary cholangitis (PBC) who already take ursodeoxycholic acid (UDCA) but still have abnormal liver blood tests. It specifically looks at people with “compensated” (stable) cirrhosis—meaning the liver disease is present but not causing severe complications right now.
This study tests fenofibrate, a medicine that may help lower liver enzymes in people with primary biliary cholangitis (PBC). It looks at how well the drug works in everyday medical practice.
Hear when a new Primary Biliary Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.